Single Dose, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Subcutaneous Injection of PolyPEPI1018 Vaccine as an Add-on Immunotherapy to the Standard-of-Care Maintenance Therapy in Subjects With Metastatic Colorectal Cancer (CRC)

Trial Profile

Single Dose, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Subcutaneous Injection of PolyPEPI1018 Vaccine as an Add-on Immunotherapy to the Standard-of-Care Maintenance Therapy in Subjects With Metastatic Colorectal Cancer (CRC)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs PolyPEPI 1018 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; First in man
  • Acronyms OBERTO
  • Sponsors Treos Bio
  • Most Recent Events

    • 14 May 2018 According to a Treos Bio media release, first patient has been dosed.
    • 11 Apr 2018 According to a Treos Bio media release, Mayo Clinic, the only U.S. site has been activated.
    • 11 Apr 2018 Status changed from not yet recruiting to recruiting, according to a Treos Bio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top